Back to top

biotechs: Archive

Zacks Equity Research

Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect

ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.

RDYNegative Net Change AMGNPositive Net Change TEVAPositive Net Change ALVONegative Net Change

Ahan Chakraborty

NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?

Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.

NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change

Ekta Bagri

3 Genomics Stocks Worth Adding to Your Portfolio in 2025

CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech

ILMNNegative Net Change BEAMPositive Net Change EDITPositive Net Change NTLAPositive Net Change PRMEPositive Net Change CRSPPositive Net Change

Zacks Equity Research

Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?

AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.

PFENegative Net Change AMGNPositive Net Change CRMDPositive Net Change DNLIPositive Net Change

Ekta Bagri

Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets.

BMYNegative Net Change MRKNegative Net Change AMGNPositive Net Change

Zacks Equity Research

INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales

Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.

NVSPositive Net Change LLYPositive Net Change BAYRYNegative Net Change INCYPositive Net Change

Zacks Equity Research

EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues

EXEL beats on Q2 earnings but misses revenues as lower collaboration income offsets strong Cabometyx sales growth.

RHHBYNegative Net Change BMYNegative Net Change EXELPositive Net Change

Zacks Equity Research

Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?

VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.

VRTXPositive Net Change CRMDPositive Net Change EXASNegative Net Change CRSPPositive Net Change

Zacks Equity Research

Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.

MRKNegative Net Change MRNAPositive Net Change EXASNegative Net Change BNTXPositive Net Change

Sundeep Ganoria

Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?

ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.

RHHBYNegative Net Change JNJPositive Net Change ABBVPositive Net Change

Zacks Equity Research

CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?

CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.

ALKSNegative Net Change VRTXPositive Net Change EXASNegative Net Change CRSPPositive Net Change

Ahan Chakraborty

Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?

Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.

AZNPositive Net Change BMYNegative Net Change MRKNegative Net Change MRNAPositive Net Change ABBVPositive Net Change

Zacks Equity Research

Biogen Gears Up to Report Q2 Earnings: Here's What to Expect

Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.

BIIBNegative Net Change LLYPositive Net Change SUPNPositive Net Change SAGENo Net Change

Ekta Bagri

Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?

BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.

BMYNegative Net Change PFENegative Net Change BNTXPositive Net Change

Shrabana Mukherjee

Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility

New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.

GHMPositive Net Change HWKNNegative Net Change KALANegative Net Change ARQNegative Net Change

Ahan Chakraborty

RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?

Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.

SNYNegative Net Change RHHBYNegative Net Change RLAYPositive Net Change RXRXPositive Net Change

Zacks Equity Research

REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?

Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.

REGNPositive Net Change VRTXPositive Net Change MRNAPositive Net Change HRMYNegative Net Change

Zacks Equity Research

Amarin Gears Up to Report Q2 Earnings: Here's What to Expect

AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.

ALKSNegative Net Change AMRNNegative Net Change EXASNegative Net Change AKROPositive Net Change

Zacks Equity Research

Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?

INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.

NVSPositive Net Change INCYPositive Net Change EXASNegative Net Change AKROPositive Net Change

Zacks Equity Research

Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues

RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

RDYNegative Net Change MRKNegative Net Change AMGNPositive Net Change ALVONegative Net Change

Ekta Bagri

Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?

BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.

BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXPositive Net Change

Zacks Equity Research

VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales

Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.

AGENPositive Net Change AMRNNegative Net Change VKTXPositive Net Change AKROPositive Net Change

Sundeep Ganoria

How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

AZNPositive Net Change PFENegative Net Change MRKNegative Net Change LLYPositive Net Change

Ekta Bagri

Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?

Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.

BMYNegative Net Change JNJPositive Net Change KROSPositive Net Change

Zacks Equity Research

Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?

EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.

ALKSNegative Net Change INCYPositive Net Change EXELPositive Net Change AKROPositive Net Change